Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    21639808 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib
2 Unknown 
Has Results
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Condition: Malignant Melanoma
Interventions: Drug: RO5185426;   Drug: dacarbazine
3 Active, not recruiting Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
Conditions: Metastatic Cancer;   Melanoma
Interventions: Drug: Vemurafenib;   Drug: Young TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
4 Recruiting Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Condition: Neoplasms
Intervention: Genetic: Blood and tumor samples

Indicates status has not been verified in more than two years